Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics
of CBT-009 eye drop in healthy volunteers.
CBT-009 has the active ingredient of atropine, which at low doses, has shown to be effective
in slowing down myopic deterioration. Current atropine products are prone to degradation once
the container is open to the air. Low pH of 3-6 is used to increase the stability of atropine
in solution, however this can irritate the eye. ADS Pharmaceutical has developed a novel
atropine formulation.